KCP
BBC icon

Kera Capital Partners’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Kera Capital Partners’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.32M Buy
101,003
+11,639
+13% +$519K 0.51% 41
2026
Q1 		$3.72M Buy
89,364
+4,394
+5% +$180K 0.46% 46
2025
Q4 		$3.47M Buy
+84,970
New +$2.89M 0.43% 49

Other funds holding BBC

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Kera Capital Partners's BBC Position: Q2 2026 in Review

Kera Capital Partners increased its Virtus Biotech Clinical Trials ETF (BBC) stake by 13% in Q2 2026, buying an estimated $519K and bringing the position to 101,003 shares worth $5.32M. The position accounts for 0.51% of the portfolio, ranked #41.

Kera Capital Partners first reported a position in BBC in Q4 2025 and has held it in 3 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

  • Kera Capital Partners held 101,003 shares of Virtus Biotech Clinical Trials ETF worth $5.32M as of Q2 2026.
  • Kera Capital Partners bought 11,639 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $519K.
  • Virtus Biotech Clinical Trials ETF made up 0.51% of Kera Capital Partners's portfolio in Q2 2026, its #41 holding.
  • Kera Capital Partners first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2025 and has held it in 3 quarters since.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.